

## Versartis Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 07-Mar-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Discovery..... 16

[Return to Table of Contents](#)

# Versartis Inc

## COMPANY OVERVIEW

Company Name	Versartis Inc
Parent Company Name	Index Ventures
Website	http://www.versartis.com/
Country	US
Number of Drugs in Active Development	2
Number of Inactive Drugs	5
Number of Patents as Owner	2
Number of Patents as Third Party	2
Number of Deals	3
Key Indications	Growth hormone deficiency, Unidentified indication, Diabetes mellitus, Blood clotting disorder, Factor VII deficiency, Glucagonoma, Hyperglycemia, Hyperinsulinemia, Obesity, Pancreas disease, Reperfusion injury, Rheumatoid arthritis, Syndrome X
Key Target-based Actions	IL-1 antagonist, Exendin 4 ligand modulator, Glucagon receptor agonist, Growth hormone ligand, Exendin 4 ligand, Factor IX agonist, Factor VII agonist, Glucagon ligand, Glutamate decarboxylase modulator
Key Technologies	Biological therapeutic, Parenteral formulation unspecified, Protein fusion, Protein recombinant, Injectable formulation, Peptide, Subcutaneous formulation, Sustained release formulation, Autoantibody, Cell culture technique, Cell therapy, Drug screening, ELISA

## COMPANY PROFILE

### SUMMARY

Versartis, formed as a joint venture between Amunix and Index Ventures, is a biotechnology company focused on the development of therapeutics for metabolic diseases and endocrine disorders using XTEN, Amunix's recombinant PEGylation (rPEG) half-life extension technology.

### COMPANY LOCATION

The company is headquartered in Redwood City, CA.

### FINANCIAL

In January 2015, the company initiated an underwritten public offering of common-stock shares and expected to raise gross proceeds of approximately \$75 million. At that time, the company expected to grant underwriters a 30-day option to purchase up to an additional 15 percent of shares. Later that month, the company priced the offering of 4,347,826 common-stock shares at a price of \$17.25 per share, with underwriters granted a 30-day option to purchase up to 652,173 additional shares. The offering was expected to close on January 27, 2015. By February 2015, the company had raised net proceeds of \$80.3 million from the offering.

In March 2014, Versartis initiated the pricing of its initial public offering of 6,000,000 shares of its common stock at an offering price of \$21 per share. The shares began trading on the NASDAQ global select market under the ticker symbol "VSAR". The underwriters were granted a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial offering price. The offering was expected to close on March 26, 2014. Later that month, the offering of 6,900,000 shares was closed and the company raised net proceeds of approximately \$132.4 million.

In February 2014, Versartis completed a \$55 million series E financing round, bringing the total capital raised to \$132 million.

In October 2013, Versartis completed a \$20 million series D financing round.

In January 2013, Versartis raised \$25 million from a series C financing by Aisling Capital.

[Return to Table of Contents](#)



In February 2011, Versartis completed a \$21 million series B financing round.


In June 2009, Versartis raised \$11 million from a series A financing round and granted an option to an investor to raise an additional \$5 million.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




## Drugs by Indication Table

Indication	Active	Inactive	Total
Metabolic disorder	1	5	6
Endocrine disease	1	4	5
Gastrointestinal disease	0	4	4
Musculoskeletal disease	1	1	2
Nutritional disorder	0	2	2
Immune disorder	0	1	1
Growth disorder	1	0	1
Unidentified indication	1	0	1
Inflammatory disease	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	1
Discontinued	2
No Development Reported	3

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Asset Divestment	1	0	0	0	1
Drug - Development/Commercialization License	0	0	1	0	1
Drug - Manufacturing/Supply	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Endocrine disease	2	6
Metabolic disorder	2	6
Growth disorder	2	4
Musculoskeletal disease	2	4
Gastrointestinal disease	0	2

### Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	1	1
Phase 1	0	4

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

[Return to Table of Contents](#)





## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	2	2	4
Gastrointestinal disease	2	1	3
Genitourinary disease	1	0	1
Growth disorder	2	1	3
Hematological disease	1	0	1
Immune disorder	2	0	2
Musculoskeletal disease	1	1	2
Neoplasm	2	0	2
Genetic disorder	1	0	1
Metabolic disorder	2	2	4
Neurological disease	1	0	1
Nutritional disorder	1	0	1
Infectious disease	1	0	1
Injury	1	0	1
Inflammatory disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### VRS-317

#### VRS-317 SNAPSHOT

<b>Drug Name</b>	VRS-317
<b>Key Synonyms</b>	somavaratan
<b>Originator Company</b>	Amunix Inc
<b>Active Companies</b>	Versartis Inc
<b>Inactive Companies</b>	Amunix Inc
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Growth hormone deficiency
<b>Target-based Actions</b>	Growth hormone receptor agonist;Growth hormone ligand
<b>Other Actions</b>	
<b>Technologies</b>	Sustained release formulation;Subcutaneous formulation;Biological therapeutic;Protein fusion;Protein recombinant
<b>Last Change Date</b>	13-Feb-2015

#### VRS-317 DEVELOPMENT PROFILE

##### SUMMARY

Versartis (a joint venture between Amunix and Index Ventures), under license from Amunix, is developing VRS-317 (human growth hormone-XTEN; hGH-XTEN; hHG-XTEN), presumed to be somavaratan, a human growth hormone (hGH) developed using Amunix's XTEN recombinant half-life extension technology, as a potential monthly sc treatment of growth hormone deficiency (GHD),. In January 2015, the company was planning to investigate the program for the potential treatment of idiopathic short stature (ISS) and Turner syndrome. In March 2014, a phase II/III trial was initiated in the US. In January 2015, positive data were reported. In January 2015, a phase III trial was initiated in pediatric patients, in the US, Western Europe and Canada. At that time, 6-month interim data were expected in 'mid-2016' and final data in early 2017. In May 2014, the company was planning to commence further trials in adult patients in Japan in 2015. In August 2014, a phase II/III registration trial for adult GHD was planned to be initiated in the second half of 2015. In February 2015, the company expected FDA approval by mid-2018. In November 2009, the company was seeking to outlicense the drug ; in October 2011, this was still the case.

#### VRS-317 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Versartis Inc	Growth hormone deficiency	Canada	Phase 3 Clinical	08-Jan-2015
Versartis Inc	Growth hormone deficiency	Europe	Phase 3 Clinical	08-Jan-2015

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Versartis Inc	Growth hormone deficiency	US	Phase 3 Clinical	10-Mar-2014
Versartis Inc	Growth hormone deficiency	Japan	Discovery	05-May-2014
Amunix Inc	Growth hormone deficiency	US	Discontinued	02-Jun-2009

## VRS-317 DRUG NAMES

Names	Type
VRS-317	Research Code
somavaratan	PINN
hGH-XTEN	Research Code
hHG-XTEN	Research Code
human growth hormone-XTEN	Research Code
rPEG HGH (injectable, growth deficiency), Versartis	
recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis	

## VRS-317 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Growth hormone deficiency											
0	0	1	1	1	1	0	2	0	0	2	4

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	1	1	0	2	0	0	2	4

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

[Return to Table of Contents](#)

**Phase 2 Clinical**

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


**Phase 1 Clinical**

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

**VRS-317 DEALS AND PATENTS**

**DEALS**

**Deals by Parent Company Chart**



**Deals by Parent Company Table**

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Index Ventures	0	0	2	0	2
Amunix Inc	1	0	0	0	1
SynCo BioPartners	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Manufacturing/Supply	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Amunix Inc	4	0	4
Index Ventures	2	1	3
Johnson & Johnson	3	0	3
Individual	1	0	1
Naia Limited	1	0	1
E I DuPont de Nemours & Co	0	1	1
Amgen Inc	0	1	1
University of Vermont	0	1	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
New use	2

## VRS-XXX

### VRS-XXX SNAPSHOT

Drug Name	VRS-XXX
Key Synonyms	
Originator Company	Amunix Inc
Active Companies	Versartis Inc
Inactive Companies	Amunix Inc
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Subcutaneous formulation;Small molecule therapeutic
Last Change Date	08-Jul-2014

### VRS-XXX DEVELOPMENT PROFILE

#### SUMMARY

Versartis (a joint venture between Amunix and Index Ventures), under license from Amunix, is investigating a once-monthly subcutaneous formulation of VRS-XXX, developed using XTEN recombinant half-life extension technology, for the potential treatment of undisclosed indication. In May 2011, the drug was listed as being under preclinical development ; in July 2014, this was still the case and at that time, the company was seeking to outlicense the program.

### VRS-XXX DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Versartis Inc	Unidentified indication	US	Discovery	02-May-2011
Amunix Inc	Unidentified indication	US	Discontinued	02-May-2011

### VRS-XXX DRUG NAMES

Names	Type
VRS-XXX	Research Code

[Return to Table of Contents](#)






VRS-XXX DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Index Ventures	0	0	1	0	1
Amunix Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

